WO2016084921A1 - Particulate composition for emitting terahertz waves - Google Patents

Particulate composition for emitting terahertz waves Download PDF

Info

Publication number
WO2016084921A1
WO2016084921A1 PCT/JP2015/083305 JP2015083305W WO2016084921A1 WO 2016084921 A1 WO2016084921 A1 WO 2016084921A1 JP 2015083305 W JP2015083305 W JP 2015083305W WO 2016084921 A1 WO2016084921 A1 WO 2016084921A1
Authority
WO
WIPO (PCT)
Prior art keywords
terahertz
particulate composition
particulate
terahertz waves
silicon oxide
Prior art date
Application number
PCT/JP2015/083305
Other languages
French (fr)
Japanese (ja)
Inventor
作男 迫田
八郎 杉本
Original Assignee
サンエス製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サンエス製薬株式会社 filed Critical サンエス製薬株式会社
Publication of WO2016084921A1 publication Critical patent/WO2016084921A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to a particulate composition that emits terahertz waves, which is used for treatment and prevention of diseases or health promotion.
  • terahertz wave research is conducted in the medical field.
  • terahertz light is highly transmissive and highly safe.
  • terahertz waves can be irradiated to a diseased part such as cancer to kill the cancer and be treated. Attempts have been made to perform warming treatment by irradiation.
  • terahertz waves are used in the medical field such as treatment, and techniques relating to this are disclosed (Patent Documents 1 and 2).
  • Patent Documents 1 and 2 disclose techniques related to a treatment apparatus that performs treatment by irradiating terahertz waves. Both techniques are excellent in that they can be treated by irradiating a diseased site such as cancer with terahertz waves. However, in any of these technologies, it is relatively difficult to continuously and easily irradiate and use the terahertz wave because the technology requires a treatment device.
  • the present invention has an object to develop a particulate composition that can use terahertz waves on a daily basis.
  • the inventors have conceived that silicon oxide emits terahertz waves, so that a compound capable of emitting terahertz waves is adsorbed on silicon oxide to form a particulate composition.
  • the inventors have completed the invention of a particulate composition that emits terahertz waves.
  • the present invention has the following configuration.
  • the first configuration of the present invention is a particulate composition characterized in that it contains a porous particulate silicon oxide as a main component and further contains a terahertz wave emitting compound capable of emitting terahertz waves.
  • the terahertz wave releasable compound is Al 2 O 3 , Fe 2 O 3 , Na 2 O, K 2 O, CaO, MgO, TiO 2 , P 2 O 5 , MnO, SO. 3.
  • the third configuration of the present invention is the particulate composition according to claim 1 or 2, wherein the maximum diameter of the particulate silicon oxide particles is 130 to 180 nm.
  • a fourth configuration of the present invention is the particulate composition according to any one of claims 1 to 3, characterized in that the use is thermotherapy by terahertz wave irradiation.
  • Composition is the particulate composition according to any one of claims 1 to 3, characterized in that the use is thermotherapy by terahertz wave irradiation.
  • an oral composition characterized in that the particulate composition according to any one of claims 1 to 5 is used as an active ingredient and terahertz waves are irradiated from the body by drinking.
  • a medical composition characterized in that terahertz waves are irradiated from outside the body using the particulate composition according to claims 1 to 5 as an active ingredient.
  • the eighth configuration of the present invention is a medical member characterized in that terahertz waves are irradiated from outside the body using the particulate composition according to claims 1 to 5 as an active ingredient.
  • this particulate composition capable of daily use of terahertz waves.
  • this particulate composition can be easily ingested, bathed, or worn as a temperate sheet, allowing terahertz waves to be easily and continuously released to the affected area without a large-scale device such as a medical device. It becomes.
  • the particulate composition of the present invention is expected to have a therapeutic and preventive effect on various diseases.
  • the particulate composition of the present invention essentially comprises a porous particulate silicon oxide and a terahertz wave releasing compound capable of emitting terahertz waves.
  • Porous particulate silicon oxide forms the basis of the present invention. That is, molecules and atoms are adsorbed in the pores of porous particulate silicon oxide, and cations and anions are exchanged between the adsorbed molecules and the like, and as a result, terahertz waves are generated. It is the principle that forms the basis of In addition, the porous particulate silicon oxide itself emits terahertz waves, and when ingested, it exhibits effects such as waste discharge, immunity improvement, blood circulation promotion and metabolism improvement.
  • the porous particulate silicon oxide has a role of emitting terahertz waves and adsorbing terahertz wave emitting compounds.
  • the porous particulate silicon oxide is not particularly limited as long as it has these roles, and various configurations can be adopted.
  • the particle size of the porous particulate silicon oxide can be appropriately adjusted according to the application, but the particle size is preferably 130 to 180 nm.
  • the terahertz compound is efficiently adsorbed, and electrons are easily exchanged between the adsorbed molecules, so that terahertz waves are effectively emitted.
  • the particle size enables the oral intake of the particulate composition, and thus has the effect of improving the handleability of the particulate composition of the present invention.
  • the terahertz wave emitting compound is adsorbed on the porous particulate silicon oxide and has a role of emitting terahertz waves.
  • the terahertz wave emitting compound is not particularly limited as long as it plays these roles and has safety according to its use, and various terahertz wave emitting compounds can be used.
  • As terahertz wave emitting compounds for example, Al 2 O 3 , Fe 2 O 3 , Na 2 O, K 2 O, CaO, MgO, TiO 2 , P 2 O 5 , MnO, SO 3 , SrO, ZrO 2 , Cl, Examples thereof include NiO, ZnO, CuO, and Rb 2 O, and these can be used alone or in combination.
  • particulate composition of the present invention other components such as pharmaceutical additives may be added according to the necessity of the dosage form.
  • additives include excipients, stabilizers, pH adjusters and the like.
  • the particulate composition of the present invention may be used in the form of particles as it is, or in various forms depending on the application, such as bead-like forms aggregated to some extent, tablets, and suspensions mixed with liquids. can do.
  • the medical composition of the present invention is prepared by mixing porous particulate silicon oxide, which is an essential composition, with terahertz wave emitting compound powder selected as any other constituent.
  • the porous granular silicon oxide is not particularly limited as long as it is a powdered silicon oxide having an ability to adsorb a terahertz compound, and can be produced by various methods.
  • industrial silicon is fired at a high temperature.
  • the temperature is not particularly limited as long as it is easy to remove and pulverize water, but it may be a high temperature of about 1000 to 1100 ° C., for example.
  • the silicon for industrial use after calcination is pulverized using a pulverizer or the like to form powder. In this case, fine particles of 330 mesh (about 40 ⁇ m diameter) or more may be used as a guide for grinding.
  • the terahertz wave compound selected as an arbitrary configuration may be prepared as a particulate powder for each compound type, or may be a particulate powder using a mixture of compounds.
  • the crystal When a single compound type material is used, the crystal may be pulverized into particles.
  • natural zeolite can be used as an example. Since natural zeolite contains oxides of magnesium and aluminum, which are terahertz compounds, it can be used as a mixture of a plurality of types of terahertz compounds. This natural zeolite is calcined at about 500 ° C for about 8 hours. This can be pulverized into a particle powder form. Furthermore, other terahertz compounds such as sodium oxide powder can be mixed and used in the pulverized particulate powder.
  • the particulate composition of the present invention is produced by mixing the particulate particulate silicon oxide (powder) thus produced with the particulate powder of the terahertz compound.
  • the produced particulate composition can be used in various forms after being subjected to various processing according to its intended use and purpose.
  • drinking particulate composition examples thereof include a particulate composition for bathing and a thermal sheet containing the particulate composition.
  • the drinking particulate composition is produced as it is or by mixing a food additive or the like for adjusting the taste as required in the produced particulate composition.
  • the produced drinkable particulate composition is suspended in addition to water or milk at the time of use.
  • the particulate composition for bathing is produced as it is or by mixing a fragrance or the like with the produced particulate composition as necessary.
  • the produced particulate composition for bathing is used by adding a necessary amount to the bath at the time of use. By using the particulate composition for bathing in this way, it is used for the purpose of irradiating terahertz waves from outside the body and exerting a therapeutic effect.
  • the thermal sheet containing the particulate composition is produced by wrapping a certain amount of particulate powder with a nonwoven fabric or the like.
  • the produced thermal sheet is used by fixing it in the vicinity of the affected part with a bandage or the like.
  • a thermal sheet to the affected breast and fix it with a bandage.
  • the manufactured thermal sheet is used for the purpose of irradiating the affected area from the outside of the body with the terahertz wave intensively and continuously to exert a therapeutic effect.
  • the medical composition of the present invention can exert therapeutic effects on various diseases by irradiating terahertz waves continuously from inside or outside the body and acting on the cell level.
  • Diseases that can exert therapeutic effects include various cancers such as pharyngeal cancer, lung cancer, uterine cancer, breast cancer, stomach cancer, colon cancer, pancreatic cancer, adrenal cortex cancer, bladder cancer, leukemia, lymphoma, Parkinson's disease, depression, It can be used for the treatment or prevention of atopic dermatitis.
  • Example, Production of Terahertz Powder >> 1. Industrial silicon was fired at a temperature of about 1100 ° C. This calcined industrial silicon was finely pulverized using 330 mesh or more as a guide. 2. Natural zeolite was calcined at about 500 ° C. for 8 hours. After firing, it was naturally cooled and then mixed with sodium oxide powder. At this time, reheating was performed as necessary. 3. Terahertz powder was prepared by mixing each powder prepared above and zirconium powder and further mixing iron powder.
  • mice (BALB / c nu / nu, 7 weeks old, female) were subcutaneously transplanted with colon cancer cell line HCT116 (1 ⁇ 10 6 cells / 50% Matrigel-100 ⁇ L). 2. On the 12th day after transplantation, where the tumor diameter grew to approximately 50 mm 3 , a powdered diet containing terahertz powder was given as a bait and administration was started. 3. The administration period was about 2 weeks, and the tumor diameter, tumor weight, and tumor appearance were evaluated.
  • FIG. 5 shows how the tumor volume changes.
  • the tumor suppressive effect was concentration-dependent.
  • FIG. 6 shows the measurement results of the tumor weight after dissection
  • FIG. 7 shows the appearance of the tumor.
  • the tumor weight in the terahertz powder-administered group was significantly smaller than that in the control, but in a concentration-dependent manner.
  • the appearance of the tumor was clearly smaller in the terahertz powder administration group than in the control group, and in particular, in the 10% administration group, most individuals were significantly smaller. 3. From these results, it was confirmed that oral administration of terahertz powder has the effect of suppressing the growth of colorectal cancer.
  • mice (BALB / c nu / nu, 7 weeks old, female) were subcutaneously transplanted with a thyroid cancer cell line 8505C (1 ⁇ 10 7 cells). 2. On the 27th day after transplantation, where the tumor diameter grew to approximately 50 mm 3 , a powdered diet containing terahertz powder was given as a bait and administration was started. 3. The administration period was about 3 weeks, and the tumor diameter, tumor weight, and tumor appearance were evaluated.
  • FIG. 8 shows how the tumor volume changes.
  • the tumor suppressive effect was concentration-dependent.
  • the measurement results of the tumor weight after dissection are shown in FIG. 9, and the appearance of the tumor is shown in FIG.
  • necrosis was observed in the tumor, so it was difficult to evaluate after dissection, so it was excluded from FIG.
  • the notation in FIG. 10 is as follows. Nec: Tumor tissue derived from an individual whose tumor has necrotized. Although there is a possibility that the terahertz powder is effective, the tumor tissue is extremely small and it is difficult to measure the weight.
  • mice (BALB / c nu / nu, 7 weeks old, female) were transplanted subcutaneously with a pancreatic cancer cell line BxPC3 (5 ⁇ 10 5 cells). 2. On the 7th day after transplantation, where the tumor diameter grew to approximately 50 mm 3 , a powdered diet containing terahertz powder was given as a bait and administration was started. 3. Tumor volume was evaluated with an administration period of about 2 weeks.
  • FIG. 11 shows how the tumor volume changes. 2. In the terahertz powder administration group, a significant tumor suppression effect was seen compared to the control. This tumor suppressive effect was concentration-dependent. 3. From these results, it was confirmed that oral administration of terahertz powder has the effect of suppressing the growth of pancreatic cancer.
  • CEA decreased from 40.9 ng / ml to 5.0 ng / ml to the normal level on April 18th.
  • thermotherapy was started in which 500g of terahertz powder in the form of beads was placed in 42 ° C hot water and bathed. The disease gradually recovered, and CT imaging in November 2013 confirmed the disappearance of lung metastases.
  • Parkinson's disease A 75-year-old female subject was diagnosed with Parkinson's disease, as a result of a crawl, hitting his head, being transported by ambulance and tested. This subject was given a prescription by taking terahertz powder for about a week, and recovered until he was able to walk, became appetite, and gradually began to walk well. Later, when diagnosed at the hospital, it was diagnosed that it was not Parkinson's disease, suggesting the possibility of Parkinson's disease recovering by taking terahertz powder.
  • depression> A 45-year-old female subject who had suffered depression for many years and was unable to go out.
  • this subject was given terahertz powder and was treated with hyperthermia, the depressive symptoms improved, and the depressive symptoms disappeared completely after 3 months of drinking.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

[Problem] To develop a particulate composition whereby terahertz waves can be utilized on an ordinary basis. [Solution] A particulate composition characterized by having porous particulate silicon oxide as a main component thereof and further including a terahertz-wave-emitting compound capable of emitting terahertz waves. The principle forming the basis of the present invention is that molecules or atoms are adsorbed in pores in the porous particulate silicon oxide, and positive ions and negative ions are exchanged between the adsorbed molecules, and as a result, terahertz waves are generated. The porous particulate silicon oxide as such emits terahertz waves, and when the porous particulate silicon oxide is orally ingested, such effects as waste product excretion, enhanced immunity, improved blood circulation, and enhanced metabolism are demonstrated.

Description

テラヘルツ波を放出する粒子状組成物Particulate composition emitting terahertz waves
　本発明は，病気の治療及び予防，もしくは健康促進に用いられる，テラヘルツ波を放出する粒子状組成物に関する。 The present invention relates to a particulate composition that emits terahertz waves, which is used for treatment and prevention of diseases or health promotion.
　テラヘルツ波とは，電磁波の一つであり，その周波数が10の12乗（1兆＝テラ）Hzと，テラヘルツ領域の周波数を有することから，その名称で呼ばれている。
　テラヘルツ波の周波数に明確な定義はないが，おおよそ100GHz～10THz（波長30μｍ），もしくは300GHz～3THz（波長100μｍ～1mm）の周波数を有するものとされている。このような周波数特性からテラヘルツ波は，直進性を有する光としての特徴，および物質透過性を有する電波としての特徴，これら２つの特徴を併せ持っている。これらの特徴から，テラヘルツ波は，直進性を有する物質透過性の高い電磁波として研究が行われている。 A terahertz wave is one of electromagnetic waves, and is called by its name because it has a frequency of 10 12 (1 trillion = tera) Hz and a frequency in the terahertz region.
Although there is no clear definition of the frequency of the terahertz wave, it is assumed to have a frequency of approximately 100 GHz to 10 THz (wavelength 30 μm) or 300 GHz to 3 THz (wavelength 100 μm to 1 mm). From such frequency characteristics, the terahertz wave has both the characteristics as light having straightness and the characteristics as radio wave having material permeability. Because of these characteristics, terahertz waves have been studied as electromagnetic waves that are straight and have high material permeability.
　テラヘルツ波の研究が行われている分野の一つとして，医療分野が挙げられる。医療分野において，テラヘルツ光は透過性が高く安全性も高いことから，例えば，癌などの疾病部位に対してテラヘルツ波を照射し癌を死滅させ治療する試みや，体表面ないし体内にテラヘルツ波を照射し加温治療を行う試みが行われている。
　このようにテラヘルツ波は，治療など医療分野において用いられ，これにかかる技術が開示されている（特許文献１，２） One area in which terahertz wave research is conducted is in the medical field. In the medical field, terahertz light is highly transmissive and highly safe. For example, terahertz waves can be irradiated to a diseased part such as cancer to kill the cancer and be treated. Attempts have been made to perform warming treatment by irradiation.
As described above, terahertz waves are used in the medical field such as treatment, and techniques relating to this are disclosed (Patent Documents 1 and 2).
特開２０１２―１２５３７２号公報JP 2012-125372 A 特開２０１４―０２３５９８号公報JP 2014-023598 A
　特許文献１および２には，テラヘルツ波を照射することにより治療を行う治療装置に関する技術が開示されている。いずれの技術においても，テラヘルツ波を，癌などの疾病部位に照射し，治療しうる点において優れた技術である。
　しかるに，これらいずれの技術においても，治療装置を必要とする技術のため，継続的かつ簡易にテラヘルツ波を照射・利用するには，比較的，困難である。 Patent Documents 1 and 2 disclose techniques related to a treatment apparatus that performs treatment by irradiating terahertz waves. Both techniques are excellent in that they can be treated by irradiating a diseased site such as cancer with terahertz waves.
However, in any of these technologies, it is relatively difficult to continuously and easily irradiate and use the terahertz wave because the technology requires a treatment device.
　上記事情を背景として本発明では，テラヘルツ波を日常的に利用することが可能な粒子状組成物の開発を課題とする。 In view of the above circumstances, the present invention has an object to develop a particulate composition that can use terahertz waves on a daily basis.
　発明者らは，鋭意研究の結果，酸化ケイ素がテラヘルツ波を放出することから，酸化ケイ素にテラヘルツ波を放出することが可能な化合物を吸着させ粒子状組成物とすることに着想し，この粒子状組成物の有用性を確認することにより，テラヘルツ波を放出する粒子状組成物の発明を完成させた。 As a result of diligent research, the inventors have conceived that silicon oxide emits terahertz waves, so that a compound capable of emitting terahertz waves is adsorbed on silicon oxide to form a particulate composition. By confirming the usefulness of the particulate composition, the inventors have completed the invention of a particulate composition that emits terahertz waves.
　本発明は，以下の構成からなる。
　本発明の第一の構成は，多孔質粒子状酸化ケイ素を主成分とし，さらにテラヘルツ波を放出可能なテラヘルツ波放出化合物を含むことを特徴とする粒子状組成物である。 The present invention has the following configuration.
The first configuration of the present invention is a particulate composition characterized in that it contains a porous particulate silicon oxide as a main component and further contains a terahertz wave emitting compound capable of emitting terahertz waves.
　本発明の第二の構成は，前記テラヘルツ波放出可能化合物が，Al2O3，Fe2O3，Na2O，K2O，CaO，MgO，TiO2，P2O5，MnO，SO3，SrO，ZrO2，Cl，NiO，ZnO，CuO，Rb2Oのいずれか又は複数から選択されることを特徴とする請求項１又は２に記載の粒子状組成物である。 According to a second configuration of the present invention, the terahertz wave releasable compound is Al 2 O 3 , Fe 2 O 3 , Na 2 O, K 2 O, CaO, MgO, TiO 2 , P 2 O 5 , MnO, SO. 3. The particulate composition according to claim 1, wherein the particulate composition is selected from any one or more of S 3 , SrO, ZrO 2 , Cl, NiO, ZnO, CuO, and Rb 2 O.
　本発明の第三の構成は，前記粒子状酸化ケイ素の粒子の最大径が，130から180nmであることを特徴とする請求項１又は２に記載の粒子状組成物である。 The third configuration of the present invention is the particulate composition according to claim 1 or 2, wherein the maximum diameter of the particulate silicon oxide particles is 130 to 180 nm.
　本発明の第四の構成は，その用途が，テラヘルツ波照射による温熱療法であることを特徴とする請求項１から３に記載の粒子状組成物である。
　本発明の第五の構成は，その用途が，癌，パーキンソン病，うつ病，アトピー性皮膚炎，これらいずれか又は複数の治療に用いられることを特徴とする請求項１から３に記載の粒子状組成物である。 A fourth configuration of the present invention is the particulate composition according to any one of claims 1 to 3, characterized in that the use is thermotherapy by terahertz wave irradiation.
The particle according to any one of claims 1 to 3, wherein the fifth aspect of the present invention is used for cancer, Parkinson's disease, depression, atopic dermatitis, or any one or more of these treatments. Composition.
　本発明の第六の構成は，請求項１から５に記載の粒子状組成物を有効成分として，飲用により体内からテラヘルツ波の照射を行うことを特徴とする経口組成物である。
　本発明の第七の構成は，請求項１から５記載の粒子状組成物を有効成分として，体外からテラヘルツ波の照射を行うことを特徴とする医療用組成物である。
　本発明の第八の構成は，請求項１から５に記載の粒子状組成物を有効成分として，体外からテラヘルツ波の照射を行うことを特徴とする医療用部材である。 According to a sixth aspect of the present invention, there is provided an oral composition characterized in that the particulate composition according to any one of claims 1 to 5 is used as an active ingredient and terahertz waves are irradiated from the body by drinking.
According to a seventh aspect of the present invention, there is provided a medical composition characterized in that terahertz waves are irradiated from outside the body using the particulate composition according to claims 1 to 5 as an active ingredient.
The eighth configuration of the present invention is a medical member characterized in that terahertz waves are irradiated from outside the body using the particulate composition according to claims 1 to 5 as an active ingredient.
　本発明により，テラヘルツ波を日常的に利用することが可能な粒子状組成物の提供が可能となった。すなわち，この粒子状組成物は，経口摂取や入浴，もしくは温帯シートとして身に付けることにより，医療装置等の大掛かりな装置がなくとも，テラヘルツ波を簡易かつ持続的に患部に放出させることが可能となる。結果として，本発明の粒子状組成物は，様々な疾患の治療および予防効果が期待される。 According to the present invention, it is possible to provide a particulate composition capable of daily use of terahertz waves. In other words, this particulate composition can be easily ingested, bathed, or worn as a temperate sheet, allowing terahertz waves to be easily and continuously released to the affected area without a large-scale device such as a medical device. It becomes. As a result, the particulate composition of the present invention is expected to have a therapeutic and preventive effect on various diseases.
粒子状組成物の反射率スペクトルを示した図The figure which showed the reflectance spectrum of particulate composition 粒子状組成物の放射スペクトルを示した図Figure showing the emission spectrum of the particulate composition 25℃における粒子状組成物の放射エネルギー分布を示した図Figure showing the radiant energy distribution of the particulate composition at 25 ° C 45℃における粒子状組成物の放射エネルギー分布を示した図Diagram showing radiant energy distribution of particulate composition at 45 ℃ 粒子状組成物を摂取させた大腸がんモデルマウスにおける腫瘍体積変化を示した図Diagram showing changes in tumor volume in colorectal cancer model mice ingested with particulate composition 粒子状組成物を摂取させた大腸がん腫瘍モデルマウスにおける腫瘍重量を比較した図Comparison of tumor weight in colorectal cancer tumor model mice ingested with particulate composition 粒子状組成物を摂取させた大腸がん腫瘍モデルマウスにおける腫瘍サイズを外観比較した図Figure of appearance comparison of tumor size in colorectal cancer tumor model mice ingested with particulate composition 粒子状組成物を摂取させた甲状腺がんモデルマウスにおける腫瘍体積変化を示した図Diagram showing changes in tumor volume in thyroid cancer model mice ingested with particulate composition 粒子状組成物を摂取させた甲状腺がん腫瘍モデルマウスにおける腫瘍重量を比較した図Comparison of tumor weight in thyroid cancer tumor model mice ingested with particulate composition 粒子状組成物を摂取させた甲状腺がん腫瘍モデルマウスにおける腫瘍サイズを外観比較した図Comparison of appearance of tumor size in thyroid cancer tumor model mice ingested with particulate composition 粒子状組成物を摂取させたすい臓がんモデルマウスにおける腫瘍体積変化を示した図Diagram showing changes in tumor volume in pancreatic cancer model mice ingested with particulate composition
　ここでは本発明の粒子状組成物について説明を行う。 Here, the particulate composition of the present invention will be described.
＜＜Ｉ．粒子状組成物の構成＞＞
　本発明の粒子状組成物は，多孔質粒子状酸化ケイ素とテラヘルツ波を放出可能なテラヘルツ波放出化合物を必須の構成とする。 << I. Composition of particulate composition >>
The particulate composition of the present invention essentially comprises a porous particulate silicon oxide and a terahertz wave releasing compound capable of emitting terahertz waves.
　多孔質粒子状酸化ケイ素は，本発明の根幹をなすものである。
　すなわち，多孔質粒子状酸化ケイ素の孔に，分子や原子が吸着され，吸着された分子等の間で，陽イオン，陰イオンのやり取りが行われ，その結果，テラヘルツ波が生じるのが本発明の根幹をなす原理である。また，多孔質粒子状酸化ケイ素そのものがテラヘルツ波を放出するとともに，経口摂取した際には，老廃物排出効果や免疫力向上効果，血行促進・代謝向上効果などの効果を発揮する。 Porous particulate silicon oxide forms the basis of the present invention.
That is, molecules and atoms are adsorbed in the pores of porous particulate silicon oxide, and cations and anions are exchanged between the adsorbed molecules and the like, and as a result, terahertz waves are generated. It is the principle that forms the basis of In addition, the porous particulate silicon oxide itself emits terahertz waves, and when ingested, it exhibits effects such as waste discharge, immunity improvement, blood circulation promotion and metabolism improvement.
　このように多孔質粒子状酸化ケイ素は，テラヘルツ波を放出するとともに，テラヘルツ波放出化合物を吸着する役割を有する。多孔質粒子状酸化ケイ素は，これらの役割を有する限り特に限定する必要はなく，種々の構成を採用することができる。
　多孔質粒子状酸化ケイ素は，その用途に応じて粒子径を適宜調整することが可能であるが，粒子径を130から180nmとすることが好ましい。これにより，テラヘルツ化合物を効率よく吸着するとともに，吸着された分子間での電子のやり取りが容易となりテラヘルツ波が効果的に放出されるという効果を有する。加えて，かかる粒子径により，粒子状組成物の経口摂取が可能となるため，本発明の粒子状組成物の取扱性を向上させる効果を有する。 Thus, the porous particulate silicon oxide has a role of emitting terahertz waves and adsorbing terahertz wave emitting compounds. The porous particulate silicon oxide is not particularly limited as long as it has these roles, and various configurations can be adopted.
The particle size of the porous particulate silicon oxide can be appropriately adjusted according to the application, but the particle size is preferably 130 to 180 nm. As a result, the terahertz compound is efficiently adsorbed, and electrons are easily exchanged between the adsorbed molecules, so that terahertz waves are effectively emitted. In addition, the particle size enables the oral intake of the particulate composition, and thus has the effect of improving the handleability of the particulate composition of the present invention.
　テラヘルツ波放出化合物は，多孔質粒子状酸化ケイ素に吸着され，テラヘルツ波を放出する役割を有する。テラヘルツ波放出化合物は，これらの役割を果たし，かつ，その用途に応じた安全性を有するものである限り特に限定する必要はなく，種々のテラヘルツ波放出化合物を用いることができる。
　テラヘルツ波放出化合物として，例えば，Al2O3，Fe2O3，Na2O，K2O，CaO，MgO，TiO2，P2O5，MnO，SO3，SrO，ZrO2，Cl，NiO，ZnO，CuO，Rb2Oなどが挙げられ，これらを単独で，もしくは組み合わせて用いることができる。 The terahertz wave emitting compound is adsorbed on the porous particulate silicon oxide and has a role of emitting terahertz waves. The terahertz wave emitting compound is not particularly limited as long as it plays these roles and has safety according to its use, and various terahertz wave emitting compounds can be used.
As terahertz wave emitting compounds, for example, Al 2 O 3 , Fe 2 O 3 , Na 2 O, K 2 O, CaO, MgO, TiO 2 , P 2 O 5 , MnO, SO 3 , SrO, ZrO 2 , Cl, Examples thereof include NiO, ZnO, CuO, and Rb 2 O, and these can be used alone or in combination.
　本発明の粒子状組成物においては，その剤型などの必要に応じて，医薬品添加物等の他の構成成分を添加しても構わない。このような添加物として，例えば，賦形剤や安定化剤，ｐＨ調整剤などが挙げられる。
　同様に，本発明の粒子状組成物は，そのまま粒子状で用いたり，ある程度凝集させたビーズ状の形態や錠剤，液体と混和させた懸濁液など，その用途に応じた種々の形態を採用することができる。 In the particulate composition of the present invention, other components such as pharmaceutical additives may be added according to the necessity of the dosage form. Examples of such additives include excipients, stabilizers, pH adjusters and the like.
Similarly, the particulate composition of the present invention may be used in the form of particles as it is, or in various forms depending on the application, such as bead-like forms aggregated to some extent, tablets, and suspensions mixed with liquids. can do.
＜＜II．医療用組成物の製造方法＞＞
　本発明の医療用組成物の製造方法について説明を行う。 << II. Method for producing medical composition >>
The manufacturing method of the medical composition of this invention is demonstrated.
　本発明の医療用組成物は，必須の組成物である多孔質粒子状酸化ケイ素に，その他任意の構成として選択されるテラヘルツ波放出化合物パウダーを混合して作製される。 The medical composition of the present invention is prepared by mixing porous particulate silicon oxide, which is an essential composition, with terahertz wave emitting compound powder selected as any other constituent.
　多孔質粒状酸化ケイ素は，テラヘルツ化合物の吸着能を有するパウダー状の酸化ケイ素である限り特に限定する必要はなく，種々の手法により作製することができる。
　一例を挙げると，まず，工業用ケイ素を高温で焼成する。これにより，工業用ケイ素の水成分が除去され酸化ケイ素の吸着能が向上するとともに，粉砕が容易となる。温度の目安としては，水の除去ならびに粉砕が容易となる限り特に限定する必要はないが，例えば1000から1100℃程度の高温とすればよい。
　焼成後の工業用ケイ素は，粉砕機等を用いて粉砕を行い，パウダー状とする。この場合の粉砕の目安として，330メッシュ（約40μm径）以上の細かな粒子とすればよい。 The porous granular silicon oxide is not particularly limited as long as it is a powdered silicon oxide having an ability to adsorb a terahertz compound, and can be produced by various methods.
As an example, first, industrial silicon is fired at a high temperature. As a result, the water component of industrial silicon is removed, the adsorption ability of silicon oxide is improved, and pulverization is facilitated. The temperature is not particularly limited as long as it is easy to remove and pulverize water, but it may be a high temperature of about 1000 to 1100 ° C., for example.
The silicon for industrial use after calcination is pulverized using a pulverizer or the like to form powder. In this case, fine particles of 330 mesh (about 40 μm diameter) or more may be used as a guide for grinding.
　任意の構成として選択されるテラヘルツ波化合物は，その化合物種ごとに粒子状パウダーとして作製してもよいし，化合物の混合体を用いて粒子状パウダーとしたものを用いてもよい。
　単一化合物種の材料を用いる場合は，その結晶体を粉砕して粒子状とすればよい。
　混合体を用いる場合，一例をあげると，天然ゼオライトを用いることができる。天然ゼオライトは，テラヘルツ化合物であるマグネシウムやアルミニウムの酸化物を含むため，複数種のテラヘルツ化合物の混合体として用いることができる。この天然ゼオライトを，約500℃で8時間ほど焼成する。これを粉砕して粒子パウダー状としたものを用いることができる。また，さらに，粉砕後の粒子状パウダーに，酸化ナトリウムパウダーなどの他のテラヘルツ化合物を混合して用いることもできる。 The terahertz wave compound selected as an arbitrary configuration may be prepared as a particulate powder for each compound type, or may be a particulate powder using a mixture of compounds.
When a single compound type material is used, the crystal may be pulverized into particles.
When using a mixture, natural zeolite can be used as an example. Since natural zeolite contains oxides of magnesium and aluminum, which are terahertz compounds, it can be used as a mixture of a plurality of types of terahertz compounds. This natural zeolite is calcined at about 500 ° C for about 8 hours. This can be pulverized into a particle powder form. Furthermore, other terahertz compounds such as sodium oxide powder can be mixed and used in the pulverized particulate powder.
　このように作製された多孔質粒子状酸化ケイ素（パウダー状）に，テラヘルツ化合物の粒子状パウダーを混合して，本発明の粒子状組成物は作製される。また，作製された粒子状組成物は，その使用用途・目的に応じて様々な加工を施した後，種々の形態を採用することができるが，例を挙げると，飲用の粒子状組成物，入浴用の粒子状組成物，粒子状組成物を含む温熱シートなどが挙げられる。 The particulate composition of the present invention is produced by mixing the particulate particulate silicon oxide (powder) thus produced with the particulate powder of the terahertz compound. In addition, the produced particulate composition can be used in various forms after being subjected to various processing according to its intended use and purpose. For example, drinking particulate composition, Examples thereof include a particulate composition for bathing and a thermal sheet containing the particulate composition.
　飲用の粒子状組成物は，そのまま，もしくは作製された粒子状組成物に必要に応じて味覚を調整するための食品用添加物等を混合して，作製される。作製された飲用粒子状組成物は，使用時に，水や牛乳等に加え懸濁させて，飲用される。
　飲用粒子状組成物は，このように用いることにより，体内（消化管内）においてテラヘルツ波を持続的に照射させ，治療効果を発揮することを目的として用いられる。 The drinking particulate composition is produced as it is or by mixing a food additive or the like for adjusting the taste as required in the produced particulate composition. The produced drinkable particulate composition is suspended in addition to water or milk at the time of use.
By using the drinking particulate composition in this way, it is used for the purpose of continuously irradiating terahertz waves in the body (in the digestive tract) and exerting a therapeutic effect.
　入浴用の粒子状組成物は，そのまま，もしくは作製された粒子状組成物に必要に応じて香料などを混合して，作製される。作製された入浴用粒子状組成物は，使用時に，お風呂に必要量加えることにより，使用される。
　入浴用粒子状組成物は，このように用いることにより，体外からテラヘルツ波を照射させ，治療効果を発揮することを目的として用いられる。 The particulate composition for bathing is produced as it is or by mixing a fragrance or the like with the produced particulate composition as necessary. The produced particulate composition for bathing is used by adding a necessary amount to the bath at the time of use.
By using the particulate composition for bathing in this way, it is used for the purpose of irradiating terahertz waves from outside the body and exerting a therapeutic effect.
　粒子状組成物を含む温熱シートは，一定量の粒子状パウダーを不織布などで包んで作製される。作製された温熱シートは，患部の近傍に包帯などで固定することにより用いられる。乳癌を例に挙げると，患部の乳房に温熱シートをあて，これを包帯で固定するなどである。
　作製された温熱シートは，このように用いることにより，体外から患部に，集中的かつ持続的にテラヘルツ波を照射させ，治療効果を発揮することを目的として用いられる。 The thermal sheet containing the particulate composition is produced by wrapping a certain amount of particulate powder with a nonwoven fabric or the like. The produced thermal sheet is used by fixing it in the vicinity of the affected part with a bandage or the like. Taking breast cancer as an example, apply a thermal sheet to the affected breast and fix it with a bandage.
The manufactured thermal sheet is used for the purpose of irradiating the affected area from the outside of the body with the terahertz wave intensively and continuously to exert a therapeutic effect.
＜＜III．医療用組成物の用途＞＞
　本発明の医療用組成物の用途について説明を行う。 << III. Applications of medical composition >>
The use of the medical composition of the present invention will be described.
　本発明の医療用組成物は，体内・体外から持続的にテラヘルツ波を照射し細胞レベルに作用することで様々な疾患の治療効果を発揮しうる。治療効果を発揮しうる疾患として，咽頭癌，肺癌，子宮癌，乳癌，胃癌，大腸癌，膵臓癌，副腎皮質癌，膀胱癌，白血病，リンパ腫など，種々の癌や，パーキンソン病，うつ病，アトピー性皮膚炎などの治療ないし予防に用いることができる。
  The medical composition of the present invention can exert therapeutic effects on various diseases by irradiating terahertz waves continuously from inside or outside the body and acting on the cell level. Diseases that can exert therapeutic effects include various cancers such as pharyngeal cancer, lung cancer, uterine cancer, breast cancer, stomach cancer, colon cancer, pancreatic cancer, adrenal cortex cancer, bladder cancer, leukemia, lymphoma, Parkinson's disease, depression, It can be used for the treatment or prevention of atopic dermatitis.
　本発明の医療用組成物について，実施例を用いてさらに詳述する。 The medical composition of the present invention will be described in further detail using examples.
＜＜実施例，テラヘルツパウダーの製造＞＞
１．工業用ケイ素を，約1100℃の温度で焼成した。この焼成した工業用ケイ素を，330メッシュ以上を目安に細かく粉砕した。
２．天然ゼオライトを，約500℃で８時間焼成した。焼成後，自然冷却した後，酸化ナトリウムパウダーと混合した。この際，必要に応じて，再加熱を行った。
３．上記で作製したそれぞれのパウダー，ならびにジルコニウムパウダーを混合し，さらに鉄パウダーを混合して，テラヘルツパウダーを作製した。 << Example, Production of Terahertz Powder >>
1. Industrial silicon was fired at a temperature of about 1100 ° C. This calcined industrial silicon was finely pulverized using 330 mesh or more as a guide.
2. Natural zeolite was calcined at about 500 ° C. for 8 hours. After firing, it was naturally cooled and then mixed with sodium oxide powder. At this time, reheating was performed as necessary.
3. Terahertz powder was prepared by mixing each powder prepared above and zirconium powder and further mixing iron powder.
Figure JPOXMLDOC01-appb-T000001
Figure JPOXMLDOC01-appb-T000001
＜＜実験例，テラヘルツパウダーの性能評価＞＞
　実施例１で作製したテラヘルツパウダーの性能評価を行うため，テラヘルツ領域での反射率を測定し，放射率を算出することを目的に行った。 << Experimental example, performance evaluation of terahertz powder >>
In order to evaluate the performance of the terahertz powder produced in Example 1, the reflectance in the terahertz region was measured and the emissivity was calculated.
１．分析方法
(1)　フーリエ変換赤外分光法を用いて行った。
(2)　正反射法により測定を行った。使用装置ならびに測定条件については，下記のとおりである。
［使用装置］
IFS-66v/S（Bruker製FT-IR）
［条件］
光源：SiC
検知器：FIR-DTGS
ビームスプリッター：T222-Broad Band Far-Infrared Beam splitter
分解能：4cm-1
積算回数：1024回
測定方法：正反射法
付属装置：正反射測定付属装置（入射角：10°，参照試料：金蒸着膜） 1. Analysis method
(1) Performed using Fourier transform infrared spectroscopy.
(2) Measurement was performed by the specular reflection method. The equipment used and the measurement conditions are as follows.
[Device used]
IFS-66v / S (Bruker FT-IR)
[conditions]
Light source: SiC
Detector: FIR-DTGS
Beam splitter: T222-Broad Band Far-Infrared Beam splitter
Resolution: 4cm -1
Integration count: 1024 times Measurement method: specular reflection method Attached device: specular reflection measurement attached device (incident angle: 10 °, reference sample: gold vapor deposition film)
２．結果と考察
(1)　試料について測定した反射率スペクトルを図１に示す。なお，反射率スペクトルは，金の反射率にて補正を行った（表示波長領域：25～100μm）。
(2)　透過率を0と仮定した場合の試料の放射率スペクトルを図２に示す。
(3)　また，25℃および45℃における放射エネルギー分布を図３，４に示す。
３．これらの結果から，25℃および45℃いずれにおいても，エネルギー放射率は理想黒体と比較して92%を超えていた。このことから，本発明のテラヘルツパウダーが，高いエネルギー放射率を有していることが分かった。 2. Results and discussion
(1) The reflectance spectrum measured for the sample is shown in FIG. The reflectance spectrum was corrected with the reflectance of gold (display wavelength range: 25 to 100 μm).
(2) Fig. 2 shows the emissivity spectrum of the sample when the transmittance is assumed to be zero.
(3) Figures 3 and 4 show the radiant energy distribution at 25 ° C and 45 ° C.
3. From these results, the energy emissivity exceeded 92% compared with the ideal blackbody at both 25 ℃ and 45 ℃. From this, it was found that the terahertz powder of the present invention has a high energy emissivity.
＜＜実験例，大腸がんモデルマウスにおけるテラヘルツパウダーの効果＞＞
　テラヘルツパウダーの抗腫瘍効果を評価するために実験を行った。 << Experimental example, effects of terahertz powder in colorectal cancer model mice >>
An experiment was conducted to evaluate the antitumor effect of terahertz powder.
＜Ｉ．実験方法＞
１．ヌードマウス（BALB/c nu/nu，７週齢，雌）に，大腸がん細胞株HCT116（1×106個/50%Matrigel-100μL）を皮下移植した。
２．腫瘍径がおよそ50mm3に成長する移植後12日目に，テラヘルツパウダーを含んだ粉末飼料を餌として与え，投与を開始した。
３．投与期間を約２週間として，腫瘍径ならびに腫瘍重量，腫瘍外観の評価を行った。 <I. Experimental method>
1. Nude mice (BALB / c nu / nu, 7 weeks old, female) were subcutaneously transplanted with colon cancer cell line HCT116 (1 × 10 6 cells / 50% Matrigel-100 μL).
2. On the 12th day after transplantation, where the tumor diameter grew to approximately 50 mm 3 , a powdered diet containing terahertz powder was given as a bait and administration was started.
3. The administration period was about 2 weeks, and the tumor diameter, tumor weight, and tumor appearance were evaluated.
＜II．実験結果＞
１．腫瘍体積の変化の様子を図５に示す。
(1)　テラヘルツパウダー投与群においては，コントロールと比較して有意な腫瘍抑制効果がみられた。
(2)　また，この腫瘍抑制効果は，濃度依存的であった。
２．解剖後の腫瘍重量の測定結果を図６に，腫瘍外観の様子を図７に示す。
(1)　テラヘルツパウダー投与群における腫瘍重量は，コントロールと比較して有意に，かつ，濃度依存的に小さいものであった。
(2)　腫瘍外観は，コントロールと比較して，テラヘルツパウダー投与群の方が明らかに小さく，特に10%投与群では，顕著に小さい個体がほとんどであった。
３．これらの結果から，テラヘルツパウダーの経口投与により，大腸がんの成長を抑制する効果があることが確認された。 <II. Experimental results>
1. FIG. 5 shows how the tumor volume changes.
(1) In the terahertz powder administration group, a significant tumor suppression effect was seen compared to the control.
(2) The tumor suppressive effect was concentration-dependent.
2. FIG. 6 shows the measurement results of the tumor weight after dissection, and FIG. 7 shows the appearance of the tumor.
(1) The tumor weight in the terahertz powder-administered group was significantly smaller than that in the control, but in a concentration-dependent manner.
(2) The appearance of the tumor was clearly smaller in the terahertz powder administration group than in the control group, and in particular, in the 10% administration group, most individuals were significantly smaller.
3. From these results, it was confirmed that oral administration of terahertz powder has the effect of suppressing the growth of colorectal cancer.
＜＜実験例，甲状腺がんモデルマウスにおけるテラヘルツパウダーの効果＞＞
　テラヘルツパウダーの抗腫瘍効果を評価するために実験を行った。 << Experimental Example, Effect of Terahertz Powder in Thyroid Cancer Model Mouse >>
An experiment was conducted to evaluate the antitumor effect of terahertz powder.
＜Ｉ．実験方法＞
１．ヌードマウス（BALB/c nu/nu，７週齢，雌）に，甲状腺がん細胞株8505C（1×107個）を皮下移植した。
２．腫瘍径がおよそ50mm3に成長する移植後27日目に，テラヘルツパウダーを含んだ粉末飼料を餌として与え，投与を開始した。
３．投与期間を約３週間として，腫瘍径ならびに腫瘍重量，腫瘍外観の評価を行った。 <I. Experimental method>
1. Nude mice (BALB / c nu / nu, 7 weeks old, female) were subcutaneously transplanted with a thyroid cancer cell line 8505C (1 × 10 7 cells).
2. On the 27th day after transplantation, where the tumor diameter grew to approximately 50 mm 3 , a powdered diet containing terahertz powder was given as a bait and administration was started.
3. The administration period was about 3 weeks, and the tumor diameter, tumor weight, and tumor appearance were evaluated.
＜II．実験結果＞
１．腫瘍体積の変化の様子を図８に示す。
(1)　テラヘルツパウダー投与群においては，コントロールと比較して有意な腫瘍抑制効果がみられた。
(2)　また，この腫瘍抑制効果は，濃度依存的であった。
２．解剖後の腫瘍重量の測定結果を図９に，腫瘍外観の様子を図１０に示す。なお，今回の検討において0.1%投与群においては，腫瘍において壊死が見られたため，解剖後の評価は困難であったので，図９からは除外している。また，図１０中の表記については，下記のとおりである。
Nec：腫瘍が壊死を起こした個体由来の腫瘍組織。テラヘルツパウダーが著効した可能性が考えられるものの，腫瘍組織が極めて微小で，重量測定も困難であったことから，図９の結果には反映させていない。
Trace：腫瘍が壊死を起こしたと考えられ，腫瘍組織の採取自体が行えなかったもの。
３．　テラヘルツパウダー投与群における腫瘍重量は，コントロールと比較して有意に小さいものであった。また，腫瘍外観は，コントロールと比較して，テラヘルツパウダー投与群の方が明らかに小かった。
４．これらの結果から，テラヘルツパウダーの経口投与により，甲状腺がんの成長を抑制する効果があることが確認された。 <II. Experimental results>
1. FIG. 8 shows how the tumor volume changes.
(1) In the terahertz powder administration group, a significant tumor suppression effect was seen compared to the control.
(2) The tumor suppressive effect was concentration-dependent.
2. The measurement results of the tumor weight after dissection are shown in FIG. 9, and the appearance of the tumor is shown in FIG. In this study, in the 0.1% administration group, necrosis was observed in the tumor, so it was difficult to evaluate after dissection, so it was excluded from FIG. In addition, the notation in FIG. 10 is as follows.
Nec: Tumor tissue derived from an individual whose tumor has necrotized. Although there is a possibility that the terahertz powder is effective, the tumor tissue is extremely small and it is difficult to measure the weight.
Trace: The tumor was thought to have necrotized and the tumor tissue itself could not be collected.
3. The tumor weight in the terahertz powder administration group was significantly smaller than the control. The appearance of the tumor was clearly smaller in the terahertz powder administration group than in the control.
4). From these results, it was confirmed that oral administration of terahertz powder has the effect of suppressing the growth of thyroid cancer.
＜＜実験例，すい臓がんモデルマウスにおけるテラヘルツパウダーの効果＞＞
　テラヘルツパウダーの抗腫瘍効果を評価するために実験を行った。 << Experimental example, effect of terahertz powder in pancreatic cancer model mouse >>
An experiment was conducted to evaluate the antitumor effect of terahertz powder.
＜Ｉ．実験方法＞
１．ヌードマウス（BALB/c nu/nu，７週齢，雌）に，すい臓がん細胞株BxPC3（5×105個）を皮下移植した。
２．腫瘍径がおよそ50mm3に成長する移植後7日目に，テラヘルツパウダーを含んだ粉末飼料を餌として与え，投与を開始した。
３．投与期間を約２週間として，腫瘍体積の評価を行った。 <I. Experimental method>
1. Nude mice (BALB / c nu / nu, 7 weeks old, female) were transplanted subcutaneously with a pancreatic cancer cell line BxPC3 (5 × 10 5 cells).
2. On the 7th day after transplantation, where the tumor diameter grew to approximately 50 mm 3 , a powdered diet containing terahertz powder was given as a bait and administration was started.
3. Tumor volume was evaluated with an administration period of about 2 weeks.
＜II．実験結果＞
１．腫瘍体積の変化の様子を図１１に示す。
２．テラヘルツパウダー投与群においては，コントロールと比較して有意な腫瘍抑制効果がみられた。また，この腫瘍抑制効果は，濃度依存的であった。
３．この結果から，テラヘルツパウダーの経口投与により，すい臓がんの成長を抑制する効果があることが確認された。 <II. Experimental results>
1. FIG. 11 shows how the tumor volume changes.
2. In the terahertz powder administration group, a significant tumor suppression effect was seen compared to the control. This tumor suppressive effect was concentration-dependent.
3. From these results, it was confirmed that oral administration of terahertz powder has the effect of suppressing the growth of pancreatic cancer.
　上記のとおり，各実験例において，腫瘍抑制効果が確認された。これらの実験例における腫瘍抑制効果の詳細なメカニズムついてはさらなる実験的な検証を行う必要があるが，テラヘルツパウダーを経口摂取することにより，腸内細菌を調整することによって抗癌作用を発揮するものと考えられる。 As described above, a tumor suppressing effect was confirmed in each experimental example. Although it is necessary to conduct further experimental verification on the detailed mechanism of the tumor suppressive effect in these experimental examples, by taking in terahertz powder orally, the antibacterial effect is demonstrated by adjusting the intestinal bacteria. Conceivable.
＜＜臨床試験例＞＞
　被験者への十分なインフォームドコンセントを得たうえで，下記のとおり，臨床試験を行い，結果を得た。 << Examples of clinical trials >>
After obtaining sufficient informed consent for the subjects, clinical trials were conducted as described below, and the results were obtained.
＜臨床試験例１．子宮癌　55歳の女性＞
　子宮癌を患った末期症状であることを医師に宣告された被験者。テラヘルツパウダーをビーズ状としたもの800gとサンゴセラミックボール400gを取り付けた温熱シートを腹部に巻き付けて1日1～3時間，肌部の温度が41～43℃になるように加熱する温熱治療を続けたところ，56日後には癌細胞の消滅が確認された。 <Clinical trial example 1. Uterine cancer 55-year-old woman>
A subject who is sentenced to a doctor as having terminal symptoms of uterine cancer. Continue the thermal treatment by wrapping a thermal sheet with 800g of terahertz powder beads and 400g of coral ceramic balls around the abdomen and heating the skin to 41-43 ° C for 1-3 hours a day. After 56 days, the disappearance of cancer cells was confirmed.
＜臨床試験例２．胃癌　62歳男性＞
　被験者にテラヘルツパウダーをビーズ状としたもの800gとサンゴセラミックボール400gを取り付けた温熱シートを腹部に巻き付けて1日1～3時間，肌部の温度が41～43℃になるように加熱する温熱治療を続けたところ，42日後には癌細胞の消滅が確認された。 <Clinical trial example 2. Gastric cancer 62-year-old man>
A thermal treatment in which a thermal sheet with 800 g of terahertz powder in the form of beads and 400 g of coral ceramic balls is wrapped around the abdomen and heated so that the skin temperature is 41 to 43 ° C for 1 to 3 hours a day After 42 days, the disappearance of cancer cells was confirmed after 42 days.
＜臨床試験例３．副腎皮質癌　65歳男性＞
　副腎皮質癌末期症状の被験者に抗がん剤治療，放射線治療の全てをやめて自宅療養に専念してもらい，テラヘルツパウダーをビーズ状としたもの800gを取り付けた温熱シートを腹部に巻き付けて1日2～4時間，肌部の温度が41～43℃になるように加熱する温熱治療を続けたところ，90日後には徐々に元気を回復し，その25日後には通常の生活が出来るようになった。 <Clinical trial example 3. Adrenal cortical cancer 65-year-old male>
A subject with end-stage symptoms of adrenocortical cancer ceased all anticancer drug treatment and radiation treatment and concentrated on home treatment, and wrapped a thermal sheet with 800g of terahertz powder in the form of beads into the abdomen 2 days a day After 4 hours of heat treatment that heats the skin to 41-43 ° C, it gradually recovered after 90 days, and after 25 days it became normal. It was.
＜臨床試験例４．白血病　93歳女性＞
　余命3カ月と診断された被験者に抗がん剤治療，放射線治療の全てをやめて自宅療養に専念してもらい，テラヘルツパウダーをビーズ状としたもの1600gを取り付けた温熱シートを腹部に巻き付けて1日1～3時間，肌部の温度が41～43℃になるように加熱する温熱治療を続けたところ，3月には起き上がれるようになり，7月には草刈りに行くまでに回復した。 <Clinical trial example 4. Leukemia 93-year-old woman>
Subjects who were diagnosed with a life expectancy of 3 months quit all anticancer drug treatment and radiation therapy and concentrate on home treatment, and wrapped a thermal sheet with 1600 g of terahertz powder beaded around the abdomen for 1 day After 1 to 3 hours of heat treatment to keep the skin temperature at 41 to 43 ° C, she began to get up in March and recovered in July before going to mowing.
＜臨床試験例５．乳癌＞
　平成23年10月乳癌（左房）が発覚し，その時点で，リンパ節，胸椎，腰椎に転移が確認された女性被験者であった。乳癌発覚後，フェマーラの服用を開始し，平成24年4月，リンパ，肺，乳癌は縮小していた。しかしながら，骨への転移癌は進行し痛みが出たため，肋骨に放射線治療，同時に抗がん剤（ティーエスワン）服用していた。
平成24年4月6日よりテラヘルツパウダーを入浴剤として使用した。すなわち，テラヘルツパウダーをビーズ状としたもの500gを42℃のお湯に入れて入浴する温熱治療を開始した。11日後の4月17日，30分散歩することが出来るまでに回復した（それまでは100m歩くことすら困難であった）。加えて，4月18日の検査にて，CEAは40.9ng/mlが5.0ng/mlと平常値にまで下がっていた。 <Clinical trial example 5. Breast cancer>
In October 2011, a female subject was found to have breast cancer (left atrium) and metastasis to lymph nodes, thoracic vertebrae, and lumbar vertebrae was confirmed at that time. Femara was started after breast cancer was detected, and in April 2012, lymph, lung, and breast cancer had shrunk. However, since metastasis to the bone progressed and became painful, radiotherapy was applied to the ribs, and at the same time, an anticancer drug (TS-1) was taken.
Terahertz powder was used as a bathing agent from April 6, 2012. In other words, thermotherapy was started in which 500 g of terahertz powder in the form of beads was placed in 42 ° C hot water and bathed. Eleven days later, on April 17, he recovered to a point where he could walk 30 times (until 100m walk was difficult until then). In addition, CEA decreased from 40.9 ng / ml to 5.0 ng / ml to the normal level on April 18th.
＜臨床試験例６，咽頭癌（肺転移あり）＞
　平成25年8月に咽頭癌の切除手術を行ったが，その時点で，肺への多発性転移が確認され，余命３カ月の宣告を受けた男性被験者であった。発覚後，テラヘルツパウダーをビーズ状としたもの500gを42℃のお湯に入れて入浴する温熱治療を開始した。徐々に病状は回復し，平成25年11月のCT撮像では，肺への転移の消失が確認された。 <Clinical trial example 6, pharyngeal cancer (with lung metastases)>
In August 2013, resection of pharyngeal cancer was performed, and at that time, multiple male metastases to the lung were confirmed, and the male subject was sentenced to life expectancy of 3 months. After the discovery, thermotherapy was started in which 500g of terahertz powder in the form of beads was placed in 42 ° C hot water and bathed. The disease gradually recovered, and CT imaging in November 2013 confirmed the disappearance of lung metastases.
＜臨床試験例７，パーキンソン病＞
　躓いて頭を打ち救急搬送され検査を行った結果，脳の若干の収縮が確認され，かつ，パーキンソン病と診断された75歳女性被験者であった。
　この被験者に対し，テラヘルツパウダーの飲用による処方を１週間ほど行ったところ，歩けるまで回復し，食欲もわくようになり，徐々に歩行もしっかりするようになった。その後，病院で診断したところ，パーキンソン病ではないと診断され，テラヘルツパウダーの飲用により，パーキンソン病が回復する可能性が示唆された。 <Clinical trial example 7, Parkinson's disease>
A 75-year-old female subject was diagnosed with Parkinson's disease, as a result of a crawl, hitting his head, being transported by ambulance and tested.
This subject was given a prescription by taking terahertz powder for about a week, and recovered until he was able to walk, became appetite, and gradually began to walk well. Later, when diagnosed at the hospital, it was diagnosed that it was not Parkinson's disease, suggesting the possibility of Parkinson's disease recovering by taking terahertz powder.
＜臨床試験例８，うつ病＞
長年，うつ病を患い，外出できない状態にまで陥っていた45歳の女性被験者であった。
　この被験者に対し，テラヘルツパウダーの飲用と温熱療法を行ったところ，うつ症状が改善し，飲用３か月でうつ症状が完全になくなり，寛解となった。

  <Clinical trial example 8, depression>
A 45-year-old female subject who had suffered depression for many years and was unable to go out.
When this subject was given terahertz powder and was treated with hyperthermia, the depressive symptoms improved, and the depressive symptoms disappeared completely after 3 months of drinking.

Claims (8)

  1. 多孔質粒子状酸化ケイ素を主成分とし，さらにテラヘルツ波を放出可能なテラヘルツ波放出化合物を含むことを特徴とする粒子状組成物 A particulate composition comprising a porous particulate silicon oxide as a main component and a terahertz wave emitting compound capable of emitting terahertz waves
  2. 前記テラヘルツ波放出可能化合物が，Al2O3，Fe2O3，Na2O，K2O，CaO，MgO，TiO2，P2O5，MnO，SO3，SrO，ZrO2，Cl，NiO，ZnO，CuO，Rb2Oのいずれか又は複数から選択されることを特徴とする請求項１又は２に記載の粒子状組成物 The terahertz wave releasable compound is Al 2 O 3 , Fe 2 O 3 , Na 2 O, K 2 O, CaO, MgO, TiO 2 , P 2 O 5 , MnO, SO 3 , SrO, ZrO 2 , Cl, 3. The particulate composition according to claim 1, wherein the particulate composition is selected from any one or more of NiO, ZnO, CuO, and Rb 2 O.
  3. 前記粒子状酸化ケイ素の粒子の最大径が，130から180nmであることを特徴とする請求項１に記載の粒子状組成物 2. The particulate composition according to claim 1, wherein a maximum diameter of the particulate silicon oxide particles is 130 to 180 nm.
  4. その用途が，テラヘルツ波照射による温熱療法であることを特徴とする請求項１から３に記載の粒子状組成物 The particulate composition according to any one of claims 1 to 3, wherein the use is thermotherapy by irradiation with terahertz waves.
  5. その用途が，癌，パーキンソン病，うつ病，アトピー性皮膚炎，これらいずれか又は複数の治療に用いられることを特徴とする請求項１から３に記載の粒子状組成物 The particulate composition according to any one of claims 1 to 3, wherein the particulate composition is used for cancer, Parkinson's disease, depression, atopic dermatitis, or any one or more of these treatments.
  6. 請求項１から５に記載の粒子状組成物を有効成分として，飲用により体内からテラヘルツ波の照射を行うことを特徴とする経口組成物 An oral composition comprising the particulate composition according to claim 1 as an active ingredient, and irradiation with terahertz waves from the body by drinking.
  7. 請求項１から５記載の粒子状組成物を有効成分として，体外からテラヘルツ波の照射を行うことを特徴とする医療用組成物 A medical composition comprising terahertz wave irradiation from outside the body, using the particulate composition according to claim 1 as an active ingredient
  8. 請求項１から５に記載の粒子状組成物を有効成分として，体外からテラヘルツ波の照射を行うことを特徴とする医療用部材

          A medical member characterized in that terahertz waves are irradiated from outside the body using the particulate composition according to claim 1 as an active ingredient.

PCT/JP2015/083305 2014-11-28 2015-11-27 Particulate composition for emitting terahertz waves WO2016084921A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014242606A JP2018104289A (en) 2014-11-28 2014-11-28 Particulate composition emitting terahertz wave
JP2014-242606 2014-11-28

Publications (1)

Publication Number Publication Date
WO2016084921A1 true WO2016084921A1 (en) 2016-06-02

Family

ID=56074468

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2015/083305 WO2016084921A1 (en) 2014-11-28 2015-11-27 Particulate composition for emitting terahertz waves

Country Status (2)

Country Link
JP (1) JP2018104289A (en)
WO (1) WO2016084921A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106599594A (en) * 2016-12-22 2017-04-26 白云绮 Human digital model based on terahertz quantum wave information and disease-diagnosing and treating system
JP2019208376A (en) * 2018-05-31 2019-12-12 株式会社大和 Feeding stuff, and feeding stuff additive
CN114480368A (en) * 2022-03-18 2022-05-13 中国科学院重庆绿色智能技术研究院 Application of broadband strong-field pulse terahertz waves in promoting apoptosis of human breast cancer cells and inhibiting proliferation of human breast cancer cells

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023101198A (en) 2022-01-07 2023-07-20 浜松ホトニクス株式会社 Optical member, optical element, and method of manufacturing optical member

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11319577A (en) * 1998-05-12 1999-11-24 Sumitomo Osaka Cement Co Ltd Dispersion of composite photocatalyst particle and its preparation and photocatalyst film
JP2004197269A (en) * 2002-12-19 2004-07-15 Sanesu Kogyo Kk Fiber fabric excellent in healthy characteristic and sanitation characteristic
JP2008248043A (en) * 2007-03-29 2008-10-16 Naris Cosmetics Co Ltd Allergen inactivator and allergen inactivating product comprising the same
JP2009120753A (en) * 2007-11-16 2009-06-04 Jgc Catalysts & Chemicals Ltd Colored alumina-silica particles, method for producing the same, and cosmetic comprising the same
JP2009240749A (en) * 2008-03-31 2009-10-22 Takuma Yoshikawa Method for reinforcing electromagnetic wave excitation by ultrasonic wave, and application apparatus thereof
JP2010083834A (en) * 2008-10-01 2010-04-15 Naris Cosmetics Co Ltd Allergen inactivator and cosmetic product containing the same
JP2011041630A (en) * 2009-08-20 2011-03-03 Tokyo Metropolitan Univ Health appliance
JP3178743U (en) * 2012-07-18 2012-09-27 株式会社アコーズ Terahertz foot massager
JP3178741U (en) * 2012-07-18 2012-09-27 株式会社アコーズ Terahertz face roller
JP3181032U (en) * 2012-11-05 2013-01-24 株式会社アコーズ Massage device
JP2013047166A (en) * 2011-08-29 2013-03-07 Jgc Catalysts & Chemicals Ltd Method for synthesizing alumina-containing mesoporous material and alumina-containing mesoporous material
JP2013209532A (en) * 2012-03-30 2013-10-10 Dowa Holdings Co Ltd Composite material of cyclodextrin and porous silica particle, and its production method, metal extractor, cesium extractor and gas adsorber
JP2014023598A (en) * 2012-07-25 2014-02-06 Univ Of Fukui Irradiation device of terahertz light converted into microbeam and therapeutic apparatus using irradiation device
JP2014024041A (en) * 2012-07-30 2014-02-06 National Institute Of Advanced Industrial & Technology METHOD FOR PRODUCING TiO2 COMPOSITE POROUS SILICA PHOTOCATALYST PARTICLE AND TiO2 COMPOSITE POROUS SILICA PHOTOCATALYST PARTICLE
JP2014117450A (en) * 2012-12-17 2014-06-30 Hiroyuki Kitagawa Treatment instrument

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11319577A (en) * 1998-05-12 1999-11-24 Sumitomo Osaka Cement Co Ltd Dispersion of composite photocatalyst particle and its preparation and photocatalyst film
JP2004197269A (en) * 2002-12-19 2004-07-15 Sanesu Kogyo Kk Fiber fabric excellent in healthy characteristic and sanitation characteristic
JP2008248043A (en) * 2007-03-29 2008-10-16 Naris Cosmetics Co Ltd Allergen inactivator and allergen inactivating product comprising the same
JP2009120753A (en) * 2007-11-16 2009-06-04 Jgc Catalysts & Chemicals Ltd Colored alumina-silica particles, method for producing the same, and cosmetic comprising the same
JP2009240749A (en) * 2008-03-31 2009-10-22 Takuma Yoshikawa Method for reinforcing electromagnetic wave excitation by ultrasonic wave, and application apparatus thereof
JP2010083834A (en) * 2008-10-01 2010-04-15 Naris Cosmetics Co Ltd Allergen inactivator and cosmetic product containing the same
JP2011041630A (en) * 2009-08-20 2011-03-03 Tokyo Metropolitan Univ Health appliance
JP2013047166A (en) * 2011-08-29 2013-03-07 Jgc Catalysts & Chemicals Ltd Method for synthesizing alumina-containing mesoporous material and alumina-containing mesoporous material
JP2013209532A (en) * 2012-03-30 2013-10-10 Dowa Holdings Co Ltd Composite material of cyclodextrin and porous silica particle, and its production method, metal extractor, cesium extractor and gas adsorber
JP3178743U (en) * 2012-07-18 2012-09-27 株式会社アコーズ Terahertz foot massager
JP3178741U (en) * 2012-07-18 2012-09-27 株式会社アコーズ Terahertz face roller
JP2014023598A (en) * 2012-07-25 2014-02-06 Univ Of Fukui Irradiation device of terahertz light converted into microbeam and therapeutic apparatus using irradiation device
JP2014024041A (en) * 2012-07-30 2014-02-06 National Institute Of Advanced Industrial & Technology METHOD FOR PRODUCING TiO2 COMPOSITE POROUS SILICA PHOTOCATALYST PARTICLE AND TiO2 COMPOSITE POROUS SILICA PHOTOCATALYST PARTICLE
JP3181032U (en) * 2012-11-05 2013-01-24 株式会社アコーズ Massage device
JP2014117450A (en) * 2012-12-17 2014-06-30 Hiroyuki Kitagawa Treatment instrument

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106599594A (en) * 2016-12-22 2017-04-26 白云绮 Human digital model based on terahertz quantum wave information and disease-diagnosing and treating system
JP2019208376A (en) * 2018-05-31 2019-12-12 株式会社大和 Feeding stuff, and feeding stuff additive
CN114480368A (en) * 2022-03-18 2022-05-13 中国科学院重庆绿色智能技术研究院 Application of broadband strong-field pulse terahertz waves in promoting apoptosis of human breast cancer cells and inhibiting proliferation of human breast cancer cells

Also Published As

Publication number Publication date
JP2018104289A (en) 2018-07-05

Similar Documents

Publication Publication Date Title
WO2016084921A1 (en) Particulate composition for emitting terahertz waves
US20170266229A1 (en) Anticancer nano-silver composition for treatment and prevention of cervical cancer, and preparation method and use thereof
CN110623992A (en) Preparation and application of folium artemisiae argyi carbon quantum dots (nanoparticles/nanoparticles)
Liu et al. Local hyperthermia for esophageal cancer in a rabbit tumor model: Magnetic stent hyperthermia versus magnetic fluid hyperthermia
Haji Mehdi Nouri et al. Enhanced induction of apoptosis and cell cycle arrest in MCF-7 breast cancer and HT-29 colon cancer cell lines via low-dose biosynthesis of selenium nanoparticles utilizing Lactobacillus casei
JP5999639B2 (en) Immunostimulating factor-bearing microparticle
CN103908470A (en) External medicinal powder for treating prickly heat, infantile eczema and eczema and producing effects of skin drying, smoothing and disinfection
CN104606261A (en) Zeolite medicinal composition, and preparation method and application thereof
JP2011115568A (en) Thermotherapy for cancer
CN102091110B (en) Chinese patent medicine capsule for treating lung cancer
CN105770045A (en) Traditional Chinese medicinal preparation for treating otitis externa
CN106031755A (en) A formula treating bacillary dysentery
CN1294929C (en) Medication for treating milk sicknss and preparation method
Zhang et al. Phase I clinical trial of Photosan combined radiation and chemotherapy in advanced gastrointestinal tract malignant tumors
Trivedi et al. Con-sciousness Energy Healing Treatment Influenced the Physicochemical and Thermal Properties of Berberine Chloride
Hemant et al. New therapeutic approaches in treating cancer
Vinogradova Current technologies in radiotherapy for non-Hodgkin lymphomas
CN104336455A (en) Red spinach porridge for treating carcinoma of uterine cervix
CN103182063A (en) Chinese patented drug pill for treating cancer
Lukach et al. Effectiveness of treatment of oropharyngeal carcinoma patients
CN104096172A (en) Traditional Chinese medicine preparation capable of resisting malignant tumors
CN105213476A (en) A kind of Chinese medicine for the treatment of nasal obstruction
Kharchenko et al. Surgical and combined treatment for primary carcinoma of the trachea
CN103656319A (en) Application for treating acute radiation-induced esophagitis
CN102626470B (en) Medicine for treating acne

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15862161

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC , EPO FORM 1205A DATED 05.09.2017.

122 Ep: pct application non-entry in european phase

Ref document number: 15862161

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP

NENP Non-entry into the national phase

Ref country code: JP

NENP Non-entry into the national phase

Ref country code: JP

NENP Non-entry into the national phase

Ref country code: JP